Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2008

View Archived Issues

New treatment options for cancer disclosed in patent literature

Cadence completes registered direct offering of shares for USD 49.3 million

Lilly launches the KwikPen insulin pen prefilled with Humalog and Humalog mixtures

Preclinical profile of novel radioligand for Abeta imaging in Alzheimer's disease

Vertex advances key programs in fourth quarter

Prostate-specific membrane antigen DNA vaccine safe in renal cell carcinoma patients

MK-0343 has different effects on healthy volunteers than lorazepam

Nycomed acquires Bradley Pharmaceuticals

Laboratory Corporation reports phase II results for ovarian cancer blood test

FDA grants IND approval to Algeta for Alpharadin for hormone-refractory prostate cancer

Mitsubishi Tanabe updates recent pipeline developments

FDA approves Kiadis Pharma's IND application for phase III clinical study of Reviroc

CHMP issues positive opinion for Mycamine

Reduced spinal cord opioid receptor mRNA and antinociception in MS mouse model

Rosiglitazone neuroprotective mechanism in experimental stroke elucidated

JuvImmune protects mice against lethal pneumonic infection

Top-line results do not meet primary endpoint in phase III MEND-CABG II trial

Biofrontera initiates phase II BF-37 study for psoriasis

Eucreas, a single-tablet combination of Galvus and metformin, approved in EU

Phase III AZ-004 trial begins in patients with schizophrenia or bipolar disorder

Novel agents for lipoprotein disorders imparted in a recent patent

Positive preliminary results reported from MacuSight's phase I sirolimus study

Recent patents report new psychopharmacologic agents

Akesis commences AKP-020 dosing in phase IIa clinical trial in type 2 diabetes

Recruitment starts for clinical phase III trial of K-301 in seborrheic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...